SEC Comment Letter 0000000000-22-013831 to TAO Synergies Inc. (TAOX)
TAO Synergies Inc.
Date: Dec. 22, 2022 · CIK: 0001571934 · Accession: 0000000000-22-013831
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268831
Letter
United States securities and exchange commission logo December 22, 2022 Robert Weinstein Chief Financial Officer Synaptogenix, Inc. 1185 Avenue of the Americas, 3rd Floor New York, New York 10036 Re:Synaptogenix, Inc. Registration Statement on Form S-3 Filed December 16, 2022 File No. 333-268831 Dear Robert Weinstein: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel Bagliebter, Esq.
Show Raw Text
United States securities and exchange commission logo
December 22, 2022
Robert Weinstein
Chief Financial Officer
Synaptogenix, Inc.
1185 Avenue of the Americas, 3rd Floor
New York, New York 10036
Re:Synaptogenix, Inc.
Registration Statement on Form S-3
Filed December 16, 2022
File No. 333-268831
Dear Robert Weinstein:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Daniel Bagliebter, Esq.